Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 9:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 3,456 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Matching Oral Placebo Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Effects of NMRA-323511 Among Healthy Elderly and Adults With Agitation Associated With Dementia Due to Alzheimer's Disease

NCT06546995
View directory record Official record
Conditions
Alzheimer's Disease, Healthy Elderly
Interventions
NMRA-323511, Placebo
Drug
Lead sponsor
Neumora Therapeutics, Inc.
Industry
Eligibility
55 Years to 90 Years
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
26
States / cities
Chandler, Arizona • Tempe, Arizona • Costa Mesa, California + 21 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 14, 2026, 9:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Safety, Tolerability, and Pharmacokinetics of E2730

NCT03054194
View directory record Official record
Conditions
Healthy Participants
Interventions
E2730, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 7, 2018 · Synced Oct 14, 2026, 9:09 PM EDT
Completed Phase 2 Interventional Results available

Study of GSK1278863 to Reduce Ischemic Events in Patients Undergoing Thoracic Aortic Aneurysm Repair

NCT01920594
View directory record Official record
Conditions
Surgical Procedures
Interventions
GSK1278863, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
13
States / cities
Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2017 · Synced Oct 14, 2026, 9:09 PM EDT
Completed Phase 3 Interventional

Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS)

NCT04458051
View directory record Official record
Conditions
Primary Progressive Multiple Sclerosis
Interventions
Tolebrutinib, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 55 Years
Enrollment
767 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
45
States / cities
La Jolla, California • Los Alamitos, California • Los Angeles, California + 41 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 14, 2026, 9:09 PM EDT
Completed Phase 2 Interventional Results available

A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Elismetrep (K-304) in the Treatment of Migraine

NCT06848075
View directory record Official record
Conditions
Migraine
Interventions
Elismetrep (K-304) 2 mg, Elismetrep (K-304) 5 mg, Elismetrep (K-304) 10 mg, Elismetrep (K-304) 20 mg, Placebo
Drug
Lead sponsor
Kallyope Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
431 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
66
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 14, 2026, 9:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1, First-in-human Study of VX-634

NCT05579431
View directory record Official record
Conditions
Alpha 1-Antitrypsin Deficiency
Interventions
VX-634, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
127 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
5
States / cities
Tempe, Arizona • Gainesville, Florida • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Oct 14, 2026, 9:09 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Effects of Basmisanil in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS) Treated With Antipsychotics

NCT02953639
View directory record Official record
Conditions
Schizophrenia
Interventions
Basmisanil, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 50 Years
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
37
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Culver City, California + 32 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2021 · Synced Oct 14, 2026, 9:09 PM EDT
Completed Phase 2 Interventional Results available

LIFT Study: A Safety, Tolerability, Efficacy, and Pharmacokinetics Study of TERN-101 in Subjects With Non-Cirrhotic Non-Alcoholic Steatohepatitis (NASH)

NCT04328077
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
TERN-101, Placebo
Drug · Other
Lead sponsor
Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 75 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
31
States / cities
Chandler, Arizona • Tucson, Arizona • Coronado, California + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2022 · Synced Oct 14, 2026, 9:09 PM EDT
Completed Phase 2 Interventional Results available

COSMIC-HF - Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure

NCT01786512
View directory record Official record
Conditions
Modified Release Oral Formulation, Left Ventricular Systolic Dysfunction, Chronic Heart Failure, History of Chronic Heart Failure, Left Ventricular Ejection Fraction, Pharmacokinetics, Echocardiogram
Interventions
Omecamtiv Mecarbil Matrix F1 Formulation, Omecamtiv Mecarbil Matrix F2 Formulation, Placebo, Omecamtiv Mecarbil Swellable Core Technology F2
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years to 85 Years
Enrollment
544 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
38
States / cities
Mobile, Alabama • Costa Mesa, California • Fresno, California + 34 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2021 · Synced Oct 14, 2026, 9:09 PM EDT
Completed Phase 3 Interventional Results available

Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder

NCT00688688
View directory record Official record
Conditions
Urinary Bladder, Overactive
Interventions
Mirabegron, Tolterodine, Placebo to Mirabegron, Placebo to Tolterodine
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
2,792 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
106
States / cities
Homewood, Alabama • Huntsville, Alabama • Mobile, Alabama + 96 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Oct 14, 2026, 9:09 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Effect of Pterostilbene on Cholesterol, Blood Pressure and Oxidative Stress

NCT01267227
View directory record Official record
Conditions
Hyperlipidemia, Blood Pressure, Oxidative Stress
Interventions
Pterostilbene 50 mg twice daily, Placebo, Grape Extract, Pterostilbene 125 mg twice daily
Drug
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years to 88 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Jan 10, 2018 · Synced Oct 14, 2026, 9:09 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis

NCT02994927
View directory record Official record
Conditions
ANCA-Associated Vasculitis
Interventions
Avacopan, Prednisone, Cyclophosphamide, Rituximab, Azathioprine
Drug · Biological
Lead sponsor
Amgen
Industry
Eligibility
12 Years and older
Enrollment
331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
41
States / cities
Huntsville, Alabama • Phoenix, Arizona • Los Angeles, California + 35 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Oct 14, 2026, 9:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Examining the Effects of CXB722 in Neuroendocrine Stress Response in Healthy Males

NCT00814931
View directory record Official record
Conditions
Stress, Anxiety
Interventions
CXB722, Placebo
Drug
Lead sponsor
CeNeRx BioPharma Inc.
Industry
Eligibility
18 Years to 34 Years · Male only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 13, 2009 · Synced Oct 14, 2026, 9:09 PM EDT
Completed Phase 2 Interventional Results available

The Safety of Molnupiravir (EIDD-2801) and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID)

NCT04405739
View directory record Official record
Conditions
SARS-CoV 2
Interventions
EIDD-2801, Placebo
Drug
Lead sponsor
Ridgeback Biotherapeutics, LP
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
11
States / cities
Los Angeles, California • Chicago, Illinois • Oak Lawn, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2023 · Synced Oct 14, 2026, 9:09 PM EDT
Completed Phase 4 Interventional Results available

Vortioxetine, 5, 10, and 20 mg, Relapse Prevention Study in Adults With Major Depressive Disorder (MDD)

NCT02371980
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Vortioxetine, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
79
States / cities
Phoenix, Arizona • Tucson, Arizona • Cerritos, California + 68 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2021 · Synced Oct 14, 2026, 9:09 PM EDT
Recruiting Phase 3 Interventional

EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

NCT07064473
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Hypertension, Cardiovascular Diseases
Interventions
Vicadrostat, Empagliflozin, Placebo matching Vicadrostat
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
11,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
208
States / cities
Anniston, Alabama • Fairhope, Alabama • Guntersville, Alabama + 171 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 14, 2026, 9:09 PM EDT
Completed Phase 4 Interventional Results available

A Study to Assess Efficacy and Safety With Solifenacin Succinate to Improve Urinary Continence After Robotic Assisted Radical Prostatectomy

NCT01371994
View directory record Official record
Conditions
Urinary Incontinence
Interventions
solifenacin succinate, Placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older · Male only
Enrollment
640 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
58
States / cities
Homewood, Alabama • Anchorage, Alaska • Tucson, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Oct 14, 2026, 9:09 PM EDT
Completed Phase 1 Interventional

Omega-3 and Therapy Study for Childhood Bipolar Disorder- Not Otherwise Specified

NCT01507753
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Omega-3 Supplementation, Psychoeducational Psychotherapy (PEP), Placebo
Drug · Behavioral · Other
Lead sponsor
L. Eugene Arnold
Other
Eligibility
7 Years to 14 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 8, 2016 · Synced Oct 14, 2026, 9:09 PM EDT
Completed Phase 2 Interventional Results available

Study of Safety, Tolerability, and Biological Activity of LAM-002A in C9ORF72-Associated Amyotrophic Lateral Sclerosis

NCT05163886
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, ALS
Interventions
LAM-002A, Placebo
Drug · Other
Lead sponsor
IRulya Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
3
States / cities
Iowa City, Iowa • Baltimore, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 14, 2026, 9:09 PM EDT
Completed Phase 2 Interventional

To Evaluate the Effects of NMRA-335140 on Symptoms of Major Depression in Participants With Bipolar II Disorder.

NCT06429722
View directory record Official record
Conditions
Major Depressive Episode Associated With Bipolar II Disorder
Interventions
NMRA-335140 80 mg, Placebo
Drug
Lead sponsor
Neumora Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
21
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Garden Grove, California + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 14, 2026, 9:09 PM EDT
Active, not recruiting Phase 3 Interventional

24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up

NCT05677451
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
LOU064 (blinded), placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 17 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
11
States / cities
Bakersfield, California • San Diego, California • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 14, 2026, 9:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of ACU-4429

NCT00703183
View directory record Official record
Conditions
Healthy
Interventions
ACU-4429, matching placebo
Drug
Lead sponsor
Kubota Vision Inc.
Industry
Eligibility
55 Years to 80 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 27, 2012 · Synced Oct 14, 2026, 9:09 PM EDT
Completed Phase 2 Interventional

Study to Determine the Safety, Tolerability, and Efficacy of Evenamide in Patients With Chronic Schizophrenia

NCT04461119
View directory record Official record
Conditions
Schizophrenia
Interventions
Evenamide, Placebo
Drug
Lead sponsor
Newron Pharmaceuticals SPA
Industry
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
Glendale, California • Gaithersburg, Maryland • Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 20, 2021 · Synced Oct 14, 2026, 9:09 PM EDT
Terminated Phase 1 Interventional

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Oral GSK4172239D Compared With Placebo in Sickle Cell Disease Participants Aged 18 to 50 Years

NCT05660265
View directory record Official record
Conditions
Hematologic Diseases, Anaemia, Sickle Cell
Interventions
GSK4172239D, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
6
States / cities
Miami, Florida • Tamarac, Florida • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 14, 2026, 9:09 PM EDT